Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
151 Cards in this Set
- Front
- Back
DURATION of a hormone’s effect depends on:
|
a) FEEDBACK
b) BIOCHEMICAL MECHANISMS |
|
Most amino acid modifications have this action
|
SLOW down DEGREDATIVE Enzymes.
|
|
Releasing or Inhibiting hormones are secreted from the
|
hypothalamus
|
|
Type of mods:
a. N-acylation b. N-formylation c. Cyclization |
Change the N-terminus
|
|
pyro-formation, via loss of a water molecule from the transition
state intermediate; symbol is < or “p” |
Cyclization
|
|
symbol is < or “p”
|
cyclization
|
|
Type of mods:
a. Convert the COOH to an amide (by adding NH2) b. Convert the COOH to an ethylamide c. Remove a terminal AA otherwise recognized by an exopeptidase: “des”AA |
Change the C-terminus
|
|
how you form a "des"AA
|
remove a terminal AA
|
|
by removing a C-terminal Gly, the resulting peptide’s new name
starts with the phrase |
“des-Gly”
|
|
Two things you can convert the COOH to when modifying a C-terminus
|
amide, ethylamide
|
|
Ways you can change the interior portion of a sequence
|
chemically modify, "des", replaced L with D
|
|
Three AAs of TRH
|
GLU-HIS-PRO
|
|
<Glu-His-Pro-NH2
|
TRH
|
|
TRH half life
|
4 minutes
|
|
Active: at picogram levels. No commercial analogs are available.
|
TRH
|
|
Diagnostic only, for HYPOTHYROIDISM’s cause (& thus treatment)
|
TRH
|
|
Therapeutic use for TRH
|
NONE
|
|
After diagnosis with TRH, if a person has a primary problem, something is wrong with their
|
thyroid
|
|
After diagnosis with TRH, if a person has a secondary problem, something is wrong with their
|
AP
|
|
After diagnosis with TRH, if a person has a tertiary problem, something is wrong with their
|
hypothalamus
|
|
Diagnostic use of TRH is in this manner
|
admin TRH IV wait, 15-30 minutes, take TRH levels
|
|
PyroGLU … GLY-NH2
|
GnRH
|
|
a 10 AA peptide
|
GnRH
|
|
duration of action of GnRH
|
3-5 hours
|
|
Activity: Release LH & FSH from Anterior Pituitary
|
GnRH
|
|
More than 3000 analogs tested
|
GnRH
|
|
What TRH would look like if it were an unmodified Glu-His-Pro at physiological pH
|
Zwitterion at N-terminus and (-) at C-terminus
|
|
Actual TRH, at physiological pH
|
Pyroglutamate at N-terminus and C-terminus is amidated
|
|
Vasopressin and Oxytocin are secreted from this lobe of the pituitary
|
posterior
|
|
MSH is secreted from this lobe of the pituitary
|
intermediate
|
|
Promote reproduction by enhanced follicle development/ovulation
|
GnRH or analog
|
|
Interfere with reproduction by RECEPTOR DOWN REGULATION
|
GnRH or analog
|
|
Diagnose potential cause of infertility (hypothalamic or pituitary)
|
GnRH or analog
|
|
How GnRH is used to treat endometriosis (by reducing levels of estrogen)
|
reducing levels of estrogen
|
|
Use of GnRH for palliative treatment of prostate cancer works by
|
reducing secretion of testosterone
|
|
Use of GnRH is palliative treatment of advanced metastatic breast cancer works by
|
reducing levels of estrogen
|
|
Used for chemical castration (as may be needed with advanced prostate cancer)
|
GnRH or analog
|
|
Used to suppress LH surges and increase chances of pregnancy
|
GnRH antagonists
|
|
aka Lutrepulse
|
Gonadorelin
|
|
pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2
|
Gonadorelin
|
|
route of Gonadorelin admin
|
IV, (not orally available)
|
|
AA #6 of Gonadorelin = D-Leu, not L-Gly
|
Leuprolide
|
|
In Leuprolide, the #6 AA is also modified and the C-terminal GLY is replaced with
|
an N-ethylamide
|
|
15-50 x as potent as GnRH
|
Leuprolide
|
|
Continuous dosage: shuts off production of estrogens or androgens.
|
Leuprolide
|
|
Used with children in cases of premature puberty to stop menstruation or to control testosterone
levels. |
Leuprolide
|
|
AA #6 of Gonadorelin = modified D-Ser; C-terminal is also modified.
|
Goserelin
|
|
It is used to treat prostate and breast cancer, to treat endometriosis, or to help thin the endometrium
prior to a hysterectomy. |
Goserelin
|
|
AA #6 of Gonadorelin is D-Ala conjugated to a naphthalene double ring structure.
|
Naferelin
|
|
Its advantage is that it is administered as a nasal spray.
|
Naferelin
|
|
Enhance fertilization: by BLOCKING the GnRH RECEPTORS they
prevent the LH surge that the anterior pituitary would otherwise induce. |
GnRH antagonists
|
|
prevent ovulation and allow greater maturation of the egg in the ovary.
|
GnRH antagonists
|
|
Effective after only 5 days of treatment, rather than the 26 days required by leuprolide
|
GnRH antagonists
|
|
Cetrorelix
|
GnRH antagonist
|
|
aka CRH, or corticorelin, or Acthrel = ACTH releasing hormone
|
CRF - Corticotropin Releasing Factor
|
|
made of 41 aa's with a synthetic version also available
|
CRF
|
|
Smallest active peptide derivative of CRH is
|
38 AA long
|
|
As with TRH and GnRH, the C-terminal
COOH is “blocked” as an amide. |
CRF
|
|
Conversion (CRF) of COOH is “blocked” as an amide back to COOH has this effect on its activity
|
drops significantly
|
|
CRH binds a receptor in the Anterior Pituitary. Signaling
involves adenylate cyclase, resulting in elevated levels of cAMP, then |
ACTH release
|
|
Primary Use: Diagnostic, for cases of pituitary defects that present as Cushing’s
Disease |
CRF
|
|
elevated levels of hydrocortisone that result from excess secretion of ACTH
|
Cushing’s Disease
|
|
Other tissues can also secrete ACTH (called __ secretion) and produce Cushing’s symptoms
|
ectopic
|
|
44 AA, but only 1- 29 are required for activity (so can be produced synthetically).
|
GRF
|
|
causes release of human Growth Hormone (hGH) from Anterior Pituitary.
|
GRF
|
|
Diagnostic for kids with idiopathic (the cause is unknown) Growth Hormone
Deficiency (GHD) |
GRF
|
|
for cases of GHD where the pituitary works fine, but hypothalamus is not working properly
|
GRF
|
|
Since GH promotes protein accumulation, __ is also approved as an “orphan drug” in AIDS to counteract protein (and associated weight) loss.
|
GRF
|
|
Dopamine and Somatostatin are both
|
inhibitory hypothalamic hormones
|
|
a catecholamine that can act both as a neurotransmitter and as a hormone
|
Dopamine
|
|
Dopamine receptors of type __, in which adenylate cyclase enzymes are inhibited
|
D2
|
|
are those responsible for the inhibitory effect of DA at the pituitary
|
Dopamine D2 receptors
|
|
Uses for DA in hormone therapy
|
NONE
|
|
Two reasons DA is not used in hormone therapy
|
1.) peripheral effects of DA in vessels
2.) broken down by MAOs and others |
|
bromocriptine
|
dopamine agonist
|
|
In women with hyperprolactinemia and a pituitary tumor, treatment with __ led to disappearance of the tumor in
45% and stabilization in another 40% over a period of 8 years followup. |
bromocriptine
|
|
Cabergoline
|
dopamine agonist with fewer side effects
|
|
Dopamine (DA), also known as
|
Prolactin-Release Inhibitory Factor, PRIF
|
|
Since elevated PRL (DA) can promote metastatic breast cancer, __
therapy used in conjunction with regular chemotherapy can be beneficial. |
bromocriptine
|
|
14-AA, cyclized peptide
|
somatostatin
|
|
inhibits release of Growth hormone from anterior pituitary
|
somatostatin
|
|
Activity requires that the peptide be cyclized
|
somatostatin
|
|
Parlodel is aka
|
Bromocriptine
|
|
If replace S-S bridge in somatostatin with an ___ the resulting
peptide has a half-life of 3 hours, instead of the 2-3 minutes exhibited by the native peptide. |
ethylene bridge (-CH2-CH2-)
|
|
why replacement of S-S bridge in somatostatin with an ethylene bridge is so effective at increasing half-life
|
reducing agents such as Glutathione (Glu-Cys-Gly) cannot break ethylene bonds
|
|
somatostatin has several sources, not just
|
the hypothalamus
|
|
Spinal Cord somatostatin is a
|
neurotransmitter
|
|
a neurotransmitter, and it induces sedation and hypothermia.
|
brain somatostatin
|
|
inhibits the secretion of gastrin
|
gut somatostatin
|
|
inhibits the release of insulin and glucagon
|
pancreas somatostatin
|
|
reason native somatostatin is not used therapeutically
|
half-life is too short
|
|
therapeutic uses include diabetes, acromegaly, and cancer of the endocrine system
|
non-radioactive somatostatin analogs
|
|
reason non-radioactive somatostatin analogs have use for treatment of diabetes
|
inhibition of glucagon secretion by somatostatin is greater than its
inhibition of insulin secretion. |
|
increases levels of blood sugar
|
glucagon
|
|
lowers blood sugar by helping it get inside cells
|
insulin
|
|
inhibit the release of several
hormones that may be hypersecreted by endocrine tumors |
somatostatin analogs
|
|
histamine, serotonin, bradykinin,
prostaglandins, vasoactive intestinal peptide |
hormones that may be hypersecreted by endocrine tumors
|
|
use of non-radioactive somatostatin analogs in the treatment of eendocrine cancers is
|
palliative (to reduce diarrhea or e-lyte imbalances)
|
|
a condition in which too much growth hormone causes an enlargement of
large bones in the hands and feet and the face, along with an enlargement of the nose and lips |
acromegaly
|
|
many tumor cell types express
RECEPTORS for |
somatostatin
|
|
use of radioactive somatostatin analogs for tumors
|
radioactivity is selectively delivered to kill the cells overexpressing somatostatin receptors
|
|
modified somatostatin analog which OVERALL most effectively inhibits the secretion of GH, insulin and glucagon
|
[D-Trp8] somatostatin
|
|
70 times more effective than native
somatostatin |
octreotide
|
|
modification of somatostatin with mirror images of aa's and COOH to OH yields
|
octreotide (70x more potent)
|
|
GH is this type of hormone
|
AP
|
|
191 AA in length, with a MW of 22,000
|
GH
|
|
GH is much larger than its active region, so the extra size
|
protects or shields the active region from enzymatic destruction
|
|
portion of GH which actually binds to the receptor
|
the C-terminal ¼ of the molecule
(somewhere within AA146-AA191) |
|
The hormone does not move in the blood as a free molecule; rather, it travels
thru the circulatory system adsorbed onto plasma proteins. |
GH
|
|
has a lower rate of inactivation by proteolytic enzymes than does free GH
|
Adsorbed GH
|
|
instead of traveling freely, these three hormones extend their half-lives by adsorbing onto the surface of plasma proteins
|
ADH, oxytocin, and GH
|
|
Today's source of GH
|
recombinant DNA technology, probably within e.coli
|
|
somatropin is aka
|
GH
|
|
Treatment for Children whose growth is abnormally slow
a. Due to lack of endogenous GH b. Due to chronic renal failure |
GH
|
|
Neutropin and Serostim are aka
|
GH
|
|
Treatment for adults with GH deficiency (due to pituitary or hypothalamic disease, radiation
therapy for cancer) |
GH
|
|
Treatment for girls with Turner’s syndrome (where one of the X-chromosomes is partially or
totally missing) – who are also unusually short |
GH
|
|
Treatment for body wasting (cachexia) due to HIV-1 or other disease
|
GH
|
|
Treatment for cardiac insufficiency in patients (wall of the ventricle is too thin, or promote growth of useful cardiac tissue in some cases of cardiac hypertrophy
– where excess myocardial mass is nonproductive) |
GH
|
|
Although GH can increase skeletal mass and strength, why should athletes beware of use for muscle gain?
|
bizarre growth patterns
|
|
What could happen to an athlete who tries to use GH to gain rapid muscle mass?
|
acromegaly, esp. is those over 18 yrs.
|
|
Site of Production is primarily in the liver (but included since they work like GH)
|
somatomedins
|
|
somatomedins are similar to
|
IGFs (Insulin-like Growth Factors)
|
|
Quite similar to insulin (they have homologies with both the A-chain and the B-chain of
insulin) |
somatomedins
|
|
nature’s own “slow release formulation”
|
transport through blood via adsorption to plasma proteins
|
|
MW a bit larger than insulin with a half-life of about 20 hours
|
somatomedins
|
|
Act together with GH to promote cartilage growth, stimulate protein
synthesis, stimulate thymidine incorporation into DNA, and stimulate cell division (mitosis). |
somatomedins
|
|
198 AA with a MW of about 23,000. Half-life is about 10 minutes. Neither
end of the peptide is blocked |
prolactin
|
|
similar in sequence to human GH (homology), and at sufficiently
high levels, bind to each others’ receptors |
prolactin
|
|
The best homology for GH and PRL is
|
only 16%
|
|
when only the first 50 AA in each GH and PRL sequence are considered
|
then the homology increases by half
|
|
Replacing only 8 AA from GH into
PRL makes a __ that readily binds the GH receptor. |
mutant PRL
|
|
Thus, homology is important, but homology between __ is more important.
|
active site amino acids
|
|
increase stability (half-life)
facilitate secretion create recognition sites |
glycosylation - covalent attachment to sugars to N of Asn thru O of Ser or Thr or HyLys
|
|
–CH2-C(=O)-NH2 becomes –CH2-C(=O)-NH-sugar chain
|
glycosylation
|
|
which are less active glycosylated proteins are non-glycosylated ones?
|
glycosylated proteins are only 20-25% as active
|
|
prolactin and TSH are both
|
glycosylated hormones
|
|
Proteins that are secreted thru the plasma membrane are often
|
glycosylated
|
|
Prolactin has a synergistic action with __ to promote mammary
gland proliferation and milk let-down |
estrogen
|
|
helps release progesterone from luteal cells, which renders the uterus suitable for imbedding of the ovum
if fertilization occurs |
Prolactin
|
|
also binds the lactogenic receptor (the receptor to which prolactin binds)
|
GH
|
|
if GH binds to the lactogenic receptor instead of prolactin, will it stimulate lactation?
|
no
|
|
Excessive levels of GH may lead to
|
galactorrhea (xs milk production, even after nursing has stopped)
|
|
high levels of PRL binding to the GH
receptor causes |
acromegaly
|
|
There is a synergistic relationship between prolactin and __ release for preparation of the uterus for implantation
|
progesterone
|
|
The main characteristic of high levels of PRL is
|
infertility
|
|
How does xs PRL possibly cause infertility?
|
prolactin receptor desensitization
|
|
increases testosterone production levels that eventually down-regulate
testosterone receptors |
Leuprolide
|
|
have high levels of prolactin and are less able to become pregnant
|
New nursing mothers
|
|
This could be nature’s way of spacing the responsibilities for child-rearing
|
prolactin receptor desensitization
|
|
In the case of prolactinemia because of a pituitary tumor, __ may be administered to inhibit prolactin secretion.
|
dopamine agonists bromocriptine or cabergoline
|